A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

The study examined genetic alterations in more than 3,200 patients with lung cancer, focusing on key genes linked to ...

There are many sub-types of NSCLC, but the three main ones are adenocarcinoma, squamous cell carcinoma and large cell ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

Nov. 11, 2024 — Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface.

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles (EVs) loaded with ...

After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Zorifertinib is the first drug in the world to launch a registration clinical trial specifically for advanced NSCLC with CNS metastases and achieve remarkable results. It is also the only* EGFR ...

An increasing number of non-smokers are being diagnosed with lung cancer for a variety of reasons. To better understand this ...

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...